Tegaserod

Tegaserod Introduction

Tegaserod is an orally administered, small neutral synthetic molecule designed to act as a partial receptor agonist of the 5-HT4 receptor on both the myenteric plexus of the gastrointestinal (GI) tract and the peripheral nervous system. It is indicated for the symptomatic treatment of women aged 18 years or older suffering from irritable bowel syndrome with constipation (IBS-C) and the treatment of chronic constipation.

Uses

Tegaserod is indicated for the symptomatic treatment of women aged 18 years or older suffering from irritable bowel syndrome with constipation (IBS-C) and the treatment of chronic constipation.

Brand Name	Tegaserod
Type
Weight
Generic	Tegaserod
Manufacturer
Available in	English বাংলা

Mechanism of Action

Tegaserod works directly on the 5-HT4 receptor, which is found in the myenteric plexus of the gastrointestinal tract and also in the peripheral nervous system. Once activated, the 5-HT4 receptor triggers an increase in GI motility, accelerates transit through the colon, and increases secretion of water and electrolytes in order to soften the stool and facilitate defecation.

How Long Does It Take to Work?

Studies of Tegaserod indicate that the onset of improvement in symptoms following treatment generally occurs within 1 to 2 weeks. Improvement continues over the course of treatment.

Absorption

Tegaserod is rapidly absorbed with peak plasma concentrations achieved in about 1 hour after oral administration. The bioavailability of Tegaserod is estimated to be around 80%.

Route of Elimination

Tegaserod is eliminated mainly via the urine. The elimination half-life of Tegaserod is approximately 11 hours.

Dosage

General recommended dosage for adult: Tegaserod 6 mg twice daily taken orally with a glass of water 30 minutes before meal. The maximum duration of treatment is 12 weeks and treatment should be discontinued after 4 weeks if no response has occurred.

Use in elderly: Dose adjustment is not necessary when administering Tegaserod to patients over 65 years old.

Use in children: There is no clinical trial in document to safety and efficacy of tegaserod in children. Therefore, it is not recommended for use in children.

The recommended dose of Tegaserod for the symptomatic treatment of irritable bowel syndrome with constipation (IBS-C) in adult women is 6 mg once daily taken orally with or without food. For the treatment of chronic constipation in adult women, the recommended dose is 12 mg once daily taken orally with or without food. The tablets should be swallowed whole with fluids.

Administration

Tegaserod should be taken orally, with or without food, every day at the same time. The tablets should be swallowed whole with fluids.

Side Effects

Common side effects associated with Tegaserod include abdominal pain, nausea, diarrhea, flatulence, headache, indigestion, vomiting, and dizziness. Less common side effects include anorexia, dyspepsia, depression, and dysgeusia.

Toxicity

Tegaserod is generally well tolerated with few side effects reported. There has been no evidence of developmental, reproductive, or other long-term toxicity reported with Tegaserod .

Precautions

Tegaserod should be used with caution in patients with renal or hepatic impairment. In addition, Tegaserod should be used with caution in patients with neurological or cardiovascular disorders, and those taking medications that are substrates for CYP3A4 or inhibitors or inducers of CYP3A4.

Interaction

Tegaserod may interact with medications that are substrates of CYP3A4 as well as medications that inhibit or induce CYP3A4 activity. Drug-drug interactions should be considered prior to starting therapy with Tegaserod .

Disease Interaction

Tegaserod should be used with caution in patients with renal or hepatic impairment, as well as those with neurological or cardiovascular disorders. Patients with these conditions should be monitored closely while on Tegaserod therapy.

Drug Interaction

Tegaserod may interact with medications that are substrates of CYP3A4 as well as medications that inhibit or induce CYP3A4 activity. Drug-drug interactions should be considered prior to starting therapy with Tegaserod .

Food Interactions

Tegaserod may be taken with or without food. The absorption of Tegaserod is not known to be affected by food.

Pregnancy Use

Tegaserod is not recommended for use during pregnancy. Animal studies have shown an increased risk of fetal abnormalities, but there are no adequate and well-controlled studies of Tegaserod use in pregnant women.

Lactation Use

Tegaserod is not recommended for use during breastfeeding. It is not known whether Tegaserod is excreted in human milk.

Acute Overdose

In the event of an overdose, the patient should be monitored closely for any signs of adverse reactions and appropriate medical intervention should be administered. There is no specific antidote for an acute overdose of Tegaserod .

Contraindication

Tegaserod is contraindicated in patients with a known hypersensitivity to Tegaserod or any of its components. Additionally, Tegaserod should not be used in patients with known or suspected gastrointestinal obstruction, history of GI perforation, and/or severe diarrhea.

Use Direction

Tegaserod should be taken orally, with or without food, every day at the same time. The tablets should be swallowed whole with fluids. For the symptomatic treatment of irritable bowel syndrome with constipation (IBS-C), the recommended dose is 6 mg once daily. For the treatment of chronic constipation, the recommended dose is 12 mg once daily.

Storage Condition

Tegaserod should be stored at room temperature away from moisture, heat, and light.

Volume of Distribution

Tegaserod has a volume of distribution of approximately 1.4 L/kg.

Half Life

The elimination half-life of Tegaserod is approximately 11 hours.

Clearance

The clearance of Tegaserod is approximately 0.25 L/h/kg.

See in details version Tegaserod also Tegaserod in bangla

Some Frequently Asked Questions About Tegaserod